The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel

The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel

Item

http://www.wikidata.org/entity/Q24651378

Q24651378

about

Impact of hypoglycemic agents on myocardial ischemic preconditioning Recent developments in adenosine receptor ligands and their potential as novel drugs The infarct-sparing effect of IB-MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A3 and A 2A receptors.Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils.Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts.Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor Activation of the A(3) adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils.Adenosine A(3) receptors regulate heart rate, motor activity and body temperature.Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant?Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor Preconditioning by isoflurane elicits mitochondrial protective mechanisms independent of sarcolemmal KATP channel in mouse cardiomyocytes.International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update Impairment of endothelial-myocardial interaction increases the susceptibility of cardiomyocytes to ischemia/reperfusion injury.Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor.Anti-ischemic effects of multivalent dendrimeric A₃ adenosine receptor agonists in cultured cardiomyocytes and in the isolated rat heart.Pharmacological and therapeutic effects of A3 adenosine receptor agonists Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.Differential Tissue-Specific Function of Adora2b in Cardioprotection.Introduction to adenosine receptors as therapeutic targets.KATP Channels in the Cardiovascular System.Investigational A₃ adenosine receptor targeting agents.Plasticity of sarcolemmal KATP channel surface expression: relevance during ischemia and ischemic preconditioning.Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor Adenosine receptors and reperfusion injury of the heart The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy.Adenosine A3 Receptor: A promising therapeutic target in cardiovascular disease.A(3) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells.Effect of HEMADO on Level of CK-MB and LDH Enzymes after Ischemia/Reperfusion Injury in Isolated Rat Heart.Polypharmacology of N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Po Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligands.Crosstalk between lysine methylation and phosphorylation of ATG16L1 dictates the apoptosis of hypoxia/reoxygenation-induced cardiomyocytes.Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity.Caspase inhibition via A3 adenosine receptors: a new cardioprotective mechanism against myocardial infarction.Adenosine A2 receptors are involved in the activation of ATP-sensitive K+ currents during metabolic inhibition in guinea pig ventricular myocytes

P2860

Q27014018-B9090186-B362-4282-A7D5-B0775278F066 Q27687253-17081460-A9CC-4DCB-A6A1-C304E02A32A5 Q30300583-DDA64333-D256-4E1C-8C16-AC4EAC781BEC Q30438821-FC16CAB2-9F48-4B20-9798-EEAF5CB4862E Q31039936-F5C8E692-A671-458C-83AE-E8BE506F1F5F Q33516043-7E23B023-E7D9-4580-8D91-69F7691AFD11 Q33759296-0493973A-3F08-4229-9042-F2B28E414617 Q33905910-28B2D1E9-F2E6-4E54-B5DD-FCD3BD32A7FC Q34025792-854466C2-19CA-4516-BD2F-CB568A302764 Q34216786-5D445CBD-F6A5-4415-A8B4-AF126F709857 Q34547891-112640F7-F16A-4CF9-ACAB-6BCC04E8FDFB Q34701303-2CCA309D-D011-45B0-87A2-43650B9C42C7 Q34875396-F1D92764-ED2E-48AC-BF1F-5A6C16529984 Q35029175-5C768506-9F40-433E-83B2-8FDCBC5B8EDD Q35218899-E6F4DDEA-4059-42DB-B4BA-EFDB4E29EE9C Q35314768-7518124C-82BC-4124-94E4-68D1CA39D4A3 Q35650779-B0CE76D2-0643-44A4-91DE-1578682AB023 Q35754166-B5AFEDC3-3294-4CBD-B26F-966F185DCD68 Q35788500-9023BC54-2FBA-408D-BABC-11C3E545A1DD Q36021597-070A726D-5984-441D-AA08-8AC1E42C6703 Q36078415-221D94C1-F30C-440A-BDEC-6F9CE5F92379 Q36153376-1D4070AD-445E-4CFC-9092-D0601CBA9069 Q36422478-43A0B37A-FB71-47CE-8432-52036633BE62 Q36731575-180FDF7E-3EA2-4C4D-B356-D3CC03CF2588 Q37071917-8F843BAF-B872-4F6F-AD8A-265AAAF09C43 Q37396368-7465F27B-A3D8-4FAE-BB6A-7DA1A25884FA Q37565166-28DEAAC5-BCBC-4636-A8D7-C88DE24D41F4 Q37957791-09A5B53C-2DCB-4B67-9915-862BE2E2D672 Q38010782-ED9B72B0-CDAC-4C63-97EC-845670743C75 Q38691918-76BA8CFF-07B1-4B71-AFDC-29A4E3B06ED3 Q41062307-57E2B13F-7199-4102-A672-16956E72346A Q43088380-A8AE928F-AB53-45F9-8A7D-01658C9B8A76 Q47964767-31732870-7745-4F92-B1CB-3406134A2AB1 Q48154944-AA446E73-317E-405E-A4FA-2C99C8E2F3C5 Q52596603-A0A5DEE8-DAB3-40F0-8E19-6877267D3675 Q53779876-06C3C2BB-E546-4A34-8EBE-D7E40F748CD0 Q54397580-0EDF22F8-0003-4015-8452-60E1F7862875 Q57099371-56B073F4-3C58-44EF-A558-5C8C40EBE76D

P2860

The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel

Item

http://www.wikidata.org/entity/Q24651378

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu